How Indian Antivenom Is Made: Snake Venom, Horse Plasma, and the Serum That Saves Lives

At the Irula Snake Catchers' Industrial Co-operative Society near Chennai, trained handlers grip a Russell's viper just behind the jaw and press its fangs against the edge of a latex-covered glass. The snake bites down. Pale yellow venom beads at the fang tips and drips into the collection vessel. The whole event takes seconds. The venom that drips out, a cocktail of phospholipase A2 enzymes, serine proteases, and haemotoxins, can destroy red blood cells, trigger uncontrolled clotting, and liquefy muscle tissue within hours of a bite.
India's antivenom supply depends on four species: the Russell's viper, the Indian cobra, the common krait, and the saw-scaled viper. These are the Big Four, responsible for the overwhelming majority of the roughly 58,000 snakebite deaths India records each year, according to a 2020 study published in eLife by Mohapatra et al. Each species produces venom with a distinct biochemical profile. Cobra venom is primarily neurotoxic, it blocks acetylcholine receptors and stops breathing. Russell's viper venom is haemotoxic and cytotoxic. Krait venom attacks the neuromuscular junction so quietly that victims often go to sleep and do not wake up. The milked samples from each species are pooled, freeze-dried, and shipped to manufacturers.
The largest producers in India are VINS Bioproducts in Hyderabad and Bharat Serums and Vaccines in Mumbai, along with the historic Haffkine Bio-Pharmaceutical Corporation in Mumbai, which has been making antivenom since the colonial era. Together they supply the polyvalent antivenom that fills most of India's public hospital stocks.Once the dried venom arrives at a production facility, it is reconstituted and diluted to a sub-lethal dose. This diluted venom is injected into horses, typically large, healthy animals kept in dedicated stables on the manufacturer's premises. The first injection is tiny. Over a schedule that can span four to six months, the dose is gradually increased. The horse's immune system, confronted repeatedly with venom proteins it cannot ignore, begins producing antibodies: immunoglobulins that bind specifically to the venom antigens and neutralise them.
The horse does not die. A well-managed immunisation schedule keeps the animal in discomfort at most. What the manufacturer is doing, essentially, is using the horse's body as a bioreactor, one that took millions of years of vertebrate evolution to build and that no synthetic process has yet fully replaced at scale. By the end of the immunisation cycle, the horse's blood is dense with antibodies targeted at the venom proteins of all four Big Four species. That is what makes the final product polyvalent: one vial, four snakes.Blood is drawn from the immunised horse, typically from the jugular vein, in volumes that are safe for the animal and repeated at intervals over the horse's working life. That whole blood is then separated. The red cells are removed and returned to the horse. What remains is plasma: the pale, protein-rich liquid fraction that carries the antibodies.

The plasma goes through a purification process called caprylic acid precipitation or ammonium sulphate fractionation, depending on the manufacturer. The goal is to strip out everything except the immunoglobulin fraction, specifically IgG antibodies, or in some processes, the F(ab')2 fragments cleaved from those antibodies. The F(ab')2 fragment retains the antigen-binding region but sheds the Fc tail, which is the part most responsible for the severe allergic reactions, anaphylaxis, serum sickness, that have historically made antivenom dangerous to administer. Removing the Fc tail reduces the reaction risk without reducing the neutralising power.
The purified antibody fraction is then tested for potency: a standard measure called ED50, the dose that protects 50% of test mice from a lethal venom challenge. If the batch passes, it is filtered, filled into glass vials under sterile conditions, and lyophilised, freeze-dried again, so it can be stored without refrigeration at room temperature for the shelf life printed on the label.A polyvalent antivenom vial contains antibodies against all four Big Four venoms simultaneously. This is a practical compromise. A treating doctor in a rural government hospital rarely knows which species bit the patient, the snake is gone, the bite mark is ambiguous, and there is no rapid diagnostic test available at the bedside. Polyvalent antivenom removes the identification problem. One product, one decision.

The compromise has a cost. Because the antibody load is split across four venom profiles, a patient bitten by a single species receives a lower effective dose of species-specific antibody than they would from a monovalent product. More vials are needed. The standard initial dose in Indian hospitals runs to 8 to 10 vials intravenously, with repeat dosing if the patient does not respond. Each vial must be administered slowly, with adrenaline drawn up and ready, because anaphylaxis remains a real risk even with purified F(ab')2 products.
There is a second geographic problem the polyvalent label obscures. India's Big Four are not uniformly distributed. The hump-nosed pit viper kills people in Kerala and Karnataka. Daboia russelii in South India has a venom profile distinct enough from its northern counterpart that standard polyvalent antivenom raised against northern Russell's viper shows reduced efficacy against southern bites, a finding documented by researchers at the Madras Crocodile Bank Trust and confirmed in subsequent studies. The vial is the same. The snake is not.Manufacturing antivenom is the part of the problem that India has largely solved at industrial scale. The part it has not solved is distribution. Antivenom is produced in a handful of facilities, cold-chain logistics across 640,000 villages is unreliable, and the patients who die from snakebite in India are disproportionately agricultural workers bitten in fields far from a hospital with functioning stock.

A 2021 analysis in PLOS Neglected Tropical Diseases estimated that more than 70% of snakebite deaths in India occur before the patient reaches a health facility. The antivenom was not unavailable in the abstract, it existed somewhere in the system. The gap was time and distance.
The biology of venom gives no grace period. Russell's viper venom begins triggering disseminated intravascular coagulation within the first hour. Krait neurotoxin can paralyse the diaphragm before the family has decided whether to go to a government hospital or a traditional healer first. The antivenom sitting in a district hospital refrigerator 40 kilometres away is, in that hour, functionally the same as no antivenom at all.
Every step of the manufacturing process, the milking, the horse, the plasma fractionation, the potency test, the lyophilised vial, is a solved problem sitting inside an unsolved one. The science of making antivenom has not changed in its essentials since Albert Calmette produced the first snake antiserum in Saigon in 1895. What has changed is the scale of the population depending on it, and the gap between where it is made and where it is needed has not closed at the same pace.